2 weeks Ago By ABMN Staff
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON – Get Free Report ) was the recipient of a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 75,500 shares, an increase of 5.
6% from the August 31st total of 71,500 shares. Currently, 0.3% of the company’s shares are sold short.
Based on an average daily trading volume, of 86,500 shares, the short-interest ratio is presently 0.9 days. Insiders Place Their Bets In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc.
acquired 57,500 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were acquired at an average price of $4.65 per share, for a total transaction of $267,375.
00. Following the acquisition, the insider now directly owns 2,660,000 shares of the company’s stock, valued at approximately $12,369,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website .
Company insiders own 14.89% of the company’s stock. Institutional Inflows and Outflows Several institutional investors have recently made changes to their positions in the stock.
Opaleye Management Inc. increased its position in shares of Eton Pharmaceuticals by 4.1% during the 4th quarter.
Opaleye Management Inc. now owns 2,529,887 shares of the company’s stock worth $11,081,000 after purchasing an additional 99,617 shares during the last quarter. Nantahala Capital Management LLC acquired a new position in shares of Eton Pharmaceuticals during the 2nd quarter worth approximately $3,095,000.
Westside Investment Management Inc. boosted its stake in shares of Eton Pharmaceuticals by 2.0% during the 2nd quarter.
Westside Investment Management Inc. now owns 585,400 shares of the company’s stock worth $1,926,000 after acquiring an additional 11,440 shares during the period. Aristides Capital LLC bought a new position in shares of Eton Pharmaceuticals during the 2nd quarter worth approximately $658,000.
Finally, Acadian Asset Management LLC boosted its stake in shares of Eton Pharmaceuticals by 13.7% during the 1st quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock worth $585,000 after acquiring an additional 18,898 shares during the period.
Institutional investors and hedge funds own 27.86% of the company’s stock. Analyst Ratings Changes View Our Latest Research Report on Eton Pharmaceuticals Eton Pharmaceuticals Stock Performance Eton Pharmaceuticals stock traded down $0.
09 during midday trading on Tuesday, reaching $5.91. The stock had a trading volume of 88,535 shares, compared to its average volume of 71,247.
The firm’s fifty day simple moving average is $4.48 and its 200-day simple moving average is $3.85.
Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $6.25.
The stock has a market capitalization of $151.83 million, a P/E ratio of 151.75 and a beta of 1.
30. Eton Pharmaceuticals ( NASDAQ:ETON – Get Free Report ) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.
12) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.05).
The company had revenue of $9.07 million for the quarter, compared to analyst estimates of $10.00 million.
Eton Pharmaceuticals had a negative return on equity of 43.62% and a negative net margin of 21.31%.
On average, sell-side analysts anticipate that Eton Pharmaceuticals will post -0.15 earnings per share for the current fiscal year. Eton Pharmaceuticals Company Profile ( Get Free Report ) Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases.
The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. Featured Stories Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
